{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:06:33Z","timestamp":1791241593903,"version":"4.1.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>CINV is a frequent adverse response to cancer treatment. There is still much to learn about the pathophysiology and initiating event of CINV, which necessitates continued research despite decades of effort. Identifying the current foci of the complex disease and assessing the scientific impact of pertinent study are made more difficult by the abundance of publications on CINV. Therefore, our goals in this article are to evaluate developments in this field, examine patterns in research domains, and gauge the expansion of CINV research production globally.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Articles about CINV published between 2012 and 2022 were found by searching the Web of Science Core Collection of Clarivate Analytics. The number of publications over time was visualized using Microsoft Office Excel 2019. CiteSpace and VOSviewer were utilized to create knowledge maps that analyzed collaborations between nations, organizations, and writers. They also presented the history of CINV research and highlighted its current areas of focus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In this study, 846 papers in all were assessed. Most publications (237, 28.01%) came from the United States. University of Toronto was the most productive institution (34, 4.01%). With 25 articles published, or 2.96% of the total, Aapro Matti published the most. The most frequently published journal was found to be Supportive Care (158, 18.68%). \u201cPalonosetron,\u201d \u201cModerately emetogenic chemotherapy,\u201d \u201c5-HT3 receptor antagonist,\u201d and \u201cNeurokinin 1 receptor antagonists\u201d were considered the hot topics. It can be seen that the research focus is on the drug treatment of chemotherapy-induced nausea and vomiting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Through bibliometric analysis, we were able to gain profound insights into CINV research for the first time. Researchers looking to uncover research frontiers and comprehend important information in this discipline may find the study\u2019s findings useful.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1369442","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T04:46:59Z","timestamp":1726202819000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Research trends on chemotherapy induced nausea and vomiting: a bibliometric analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Chunhui","family":"Ning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yansong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjie","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann. Oncol."},{"key":"B2","first-page":"S259","article-title":"Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies","volume":"23","author":"Adel","year":"2017","journal-title":"Am. J. Manag. Care."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/jco.2010.34.4614","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"29","author":"Basch","year":"","journal-title":"J. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/jco.2010.34.4614","article-title":"Antiemetics: American society of clinical oncology clinical practice guideline update","volume":"29","author":"Basch","year":"","journal-title":"J. Clin. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/jco.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/asi.20317","article-title":"CiteSpace \u2161:Detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"28","author":"Chen","year":"2009","journal-title":"J. China Soc. Sci. Tech. Inf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e28473","DOI":"10.1002\/pbc.28473","article-title":"Neuroblastoma","volume":"68","author":"Chung","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.breast.2020.11.002","article-title":"A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"54","author":"Clemons","year":"2020","journal-title":"Breast"},{"key":"B9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s13312-010-0023-4","article-title":"Management of chemotherapy-induced nausea and vomiting","volume":"47","author":"Dewan","year":"2010","journal-title":"Indian Pediatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"102512","DOI":"10.1016\/j.ctrv.2023.102512","article-title":"Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis","volume":"115","author":"Filetti","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11192-016-1885-6","article-title":"Scientific workflows for bibliometrics","volume":"107","author":"Guler","year":"2016","journal-title":"Scientometrics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"100278","DOI":"10.1016\/j.ctarc.2020.100278","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends","volume":"26","author":"Gupta","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"B13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/s1470-2045(19)30678-3","article-title":"Olanzapine 5\u00a0mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00520-007-0380-2","article-title":"Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S","volume":"16","author":"Henry","year":"2008","journal-title":"Support. Care Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/cco.0000000000000450","article-title":"The latest consensus on antiemetics","volume":"30","author":"Herrstedt","year":"2018","journal-title":"Curr. Opin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Drug therapy: chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/jnci\/83.9.613","article-title":"Serotonin antagonists: a new class of antiemetic agents","volume":"83","author":"Hesketh","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/jco.2003.01.095","article-title":"The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group","volume":"21","author":"Hesketh","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/jco.2017.74.4789","article-title":"Antiemetics: American society of clinical oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1213\/01.Ane.0000130003.68288.C7","article-title":"Dexamethasone has a central antiemetic mechanism in decerebrated cats","volume":"99","author":"Ho","year":"2004","journal-title":"Anesth. Analg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1507\/endocrj.47.667","article-title":"A case of isolated ACTH deficiency who developed autoimmune-mediated hypothyroidism and impaired water diuresis during glucocorticoid replacement therapy","volume":"47","author":"Kageyama","year":"2000","journal-title":"Endocr. J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"812","DOI":"10.2146\/ajhp160227","article-title":"New options and controversies in the management of chemotherapy-induced nausea and vomiting","volume":"74","author":"Koth","year":"2017","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5172\/impp.12.1.26","article-title":"Investigating the structure of regional innovation system research through keyword co-occurrence and social network analysis","volume":"12","author":"Lee","year":"2010","journal-title":"Innovation-Management Policy and Pract."},{"key":"B24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/children7090140","article-title":"Efficacy of olanzapine for high and moderate emetogenic chemotherapy in children","volume":"7","author":"Lee","year":"2020","journal-title":"Child. (Basel)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.physa.2016.01.017","article-title":"Evolutionary features of academic articles co-keyword network and keywords co-occurrence network: based on two-mode affiliation network","volume":"450","author":"Li","year":"2016","journal-title":"Phys. a-Statistical Mech. Its Appl."},{"key":"B26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2147\/tcrm.S89215","article-title":"Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant\/palonosetron","volume":"12","author":"Lorusso","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"B27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jand.2015.10.020","article-title":"Chemotherapy-induced nausea and vomiting: a narrative review to inform dietetics practice","volume":"116","author":"Marx","year":"2016","journal-title":"J. Acad. Nutr. Diet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/nure.12016","article-title":"Ginger (Zingiber officinale) and chemotherapy-induced nausea and vomiting: a systematic literature review","volume":"71","author":"Marx","year":"2013","journal-title":"Nutr. Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00005-009-0001-5","article-title":"New developments in the use of citation analysis in research evaluation","volume":"57","author":"Moed","year":"2009","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s1470-2045(19)30791-0","article-title":"Time to re-think the olanzapine dose","volume":"21","author":"Molassiotis","year":"2020","journal-title":"Lancet Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejphar.2013.08.048","article-title":"Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting","volume":"722","author":"Navari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.47176\/mjiri.35.20","article-title":"COVID-19 research progress: bibliometrics and visualization analysis","volume":"35","author":"Okhovati","year":"2021","journal-title":"Med. J. Islam. Repub. Iran."},{"key":"B34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00520-016-3391-z","article-title":"2016 Updated MASCC\/ESMO Consensus Recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential","volume":"25","author":"Olver","year":"2017","journal-title":"Support. Care Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0184360","DOI":"10.1371\/journal.pone.0184360","article-title":"Incidence and severity of self-reported chemotherapy side effects in routine care: a prospective cohort study","volume":"12","author":"Pearce","year":"2017","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1002\/cncr.11433","article-title":"Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America","volume":"97","author":"Poli-Bigelli","year":"2003","journal-title":"Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/annonc\/mdp194","article-title":"Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting","volume":"20","author":"Roila","year":"2009","journal-title":"Ann. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/s1470-2045(08)70313-9","article-title":"Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial","volume":"10","author":"Saito","year":"2009","journal-title":"Lancet Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12904-020-00559-4","article-title":"The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature","volume":"19","author":"Saudemont","year":"2020","journal-title":"BMC Palliat. Care."},{"key":"B40","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00520-013-1999-9","article-title":"Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)","volume":"22","author":"Schwartzberg","year":"2014","journal-title":"Support. Care Cancer."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s11096-018-0649-1","article-title":"Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy","volume":"40","author":"Slimano","year":"2018","journal-title":"Int. J. Clin. Pharm."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2147\/cmar.S280995","article-title":"Antiemetic efficacy of adding olanzapine 5\u00a0mg to aprepitant, palonosetron and dexamethasone-sparing after day two for cancer patients receiving anthracycline and cyclophosphamide","volume":"13","author":"Suehiro","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/00000542-200409000-00014","article-title":"Inhibitory effect of glucocorticoids on human-cloned 5-hydroxytryptamine3A receptor expressed in xenopus oocytes","volume":"101","author":"Suzuki","year":"2004","journal-title":"Anesthesiology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00280-019-03868-5","article-title":"Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting","volume":"84","author":"Tanaka","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12916-016-0761-9","article-title":"Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis","volume":"14","author":"Tricco","year":"2016","journal-title":"BMC Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","article-title":"Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy","volume":"94","author":"Vardy","year":"2006","journal-title":"Br. J. Cancer."},{"key":"B47","doi-asserted-by":"publisher","first-page":"705866","DOI":"10.3389\/fonc.2021.705866","article-title":"The balance between the effectiveness and safety for chemotherapy-induced nausea and vomiting of different doses of olanzapine (10\u00a0mg versus 5\u00a0mg): a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1200\/jco.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy","volume":"23","author":"Warr","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1126\/science.1136099","article-title":"The increasing dominance of teams in production of knowledge","volume":"316","author":"Wuchty","year":"2007","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1002\/asi.21128","article-title":"Applying centrality measures to impact analysis: a coauthorship network analysis","volume":"60","author":"Yan","year":"2009","journal-title":"J. Am. Soc. Inf. Sci. Technol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1634\/theoncologist.2018-0140","article-title":"Effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis","volume":"24","author":"Yokoe","year":"2019","journal-title":"Oncologist"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.7314\/apjcp.2016.17.4.1661","article-title":"Efficacy and safety of neurokinin-1 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Yuan","year":"2016","journal-title":"Asian pac. J. Cancer Prev."},{"key":"B53","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/annonc\/mdx698","article-title":"A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)","volume":"29","author":"Zhang","year":"2018","journal-title":"Ann. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"101771","DOI":"10.1016\/j.eclinm.2022.101771","article-title":"A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)","volume":"55","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1369442\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T04:47:05Z","timestamp":1726202825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1369442\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":54,"alternative-id":["10.3389\/fphar.2024.1369442"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1369442","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"article-number":"1369442"}}